HIGHLIGHTS
- who: FoundationOne assay and colleagues from the Université Côte d'Azur, Nice, France Institute of Pathology, University Hospital Heidelberg, Heidelberg, Germany have published the research: In-House Implementation of Tumor Mutational Burden Testing to Predict Durable Clinical Benefit in Non-Small Cell Lung Cancer and Melanoma Patients, in the Journal: (JOURNAL)
- what: The study is limited in size and consequently, the treatment outcome was analyzed without stratifying the patients for their respective treatment and by combining both first-line and second-line treatment. The study was performed in accordance to the guideline of the . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.